ID: ALA4291366

Max Phase: Preclinical

Molecular Formula: C23H24O4

Molecular Weight: 364.44

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccccc1/C=C1\CCC/C(=C\c2ccc(OC)c(OC)c2)C1=O

Standard InChI:  InChI=1S/C23H24O4/c1-25-20-10-5-4-7-17(20)15-19-9-6-8-18(23(19)24)13-16-11-12-21(26-2)22(14-16)27-3/h4-5,7,10-15H,6,8-9H2,1-3H3/b18-13+,19-15+

Standard InChI Key:  HUTVRDNYAJBQLV-HQSZAHFGSA-N

Associated Targets(Human)

SW-620 52400 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A549 127892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HT-1080 3966 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MCF7 126967 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NHDF 1164 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 364.44Molecular Weight (Monoisotopic): 364.1675AlogP: 4.93#Rotatable Bonds: 5
Polar Surface Area: 44.76Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 5.12CX LogD: 5.12
Aromatic Rings: 2Heavy Atoms: 27QED Weighted: 0.71Np Likeness Score: -0.37

References

1. Leong SW, Chia SL, Abas F, Yusoff K..  (2018)  Asymmetrical meta-methoxylated diarylpentanoids: Rational design, synthesis and anti-cancer evaluation in-vitro.,  157  [PMID:30138803] [10.1016/j.ejmech.2018.08.039]

Source